FDA backs 3 psychedelic drug studies for mental illness
Ella Ruder / beckershospitalreview - The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The vouchers were issued to companies studying psilocybin for treatment-resistant depression and major depressive disorder as well…
AI Summary: The FDA announced a targeted push to accelerate clinical research into psychedelics for mental illness, issuing three commissioner vouchers to support rigorous trials of psychedelic therapies. The move aims to fast-track evidence generation under regulatory oversight, signalling growing agency willingness to explore unconventional treatments while keeping safety and trial standards squarely in view.
- FDA voucher push and federal policy shift (5)
- Psilocybin and brain science (4)
- Real-world use, safety and clinical readiness (3)
- All Other Stories
FDA voucher push and federal policy shift
Psilocybin and brain science
Real-world use, safety and clinical readiness
All Other Stories
Related Stories
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 2 months
US gray‑market peptides face scrutiny as FDA panel debate looms / 6 days
The peptide problem: Hype outruns evidence, researchers caution / 2 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
FDA escalates push to withdraw Amgen’s Tavneos; Amgen updates label / 2 months
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 2 months
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Alzheimer's disease, Public Health, Government Policy, Infectious Disease and look for the RSS link.
StackHealth Time Machine